Business Context and Reporting Period
This Form 8-K was filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on February 28, 2019. The registrant is a Delaware corporation and an emerging growth company. The report addresses corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to Item 5.02 regarding officer departures and contains no financial data.
Material Changes
- Board Resignation: P. Kent Hawryluk resigned from the Board of Directors effective February 28, 2019.
- Reason for Departure: The resignation was not due to any disagreement regarding the Company's operations, policies, or practices.
- Board Composition: Following the resignation, the Board size was reduced from six to five members.
Guidance, Outlook, and Risks
The filing does not contain guidance, outlook, management commentary on financial performance, or specific risk factors beyond the standard disclosure of the director's departure. No unusual items or contingencies were reported in this document.
Investor Verification Checklist
- Verify the current composition of the Board of Directors following the reduction to five members.
- Confirm whether the resignation of P. Kent Hawryluk impacts any ongoing strategic initiatives or committee assignments.
- Review subsequent filings for any new director appointments to fill the vacancy.